Wayne State University (WSU) - Karmanos Cancer Institute (KCI) has been an active institutional member office cooperative group system since 1972, an NCI designated Comprehensive Cancer Center since 1978, a parent institution Phase I (U01) since 1993, and a member of a Phase 1 consortium (N01) since 2000. We have an active membership in the Southwest Oncology Group (SWOG), Radiation Oncology Group (RTOG), and Gynecologic Oncology Group (GOG) with participation in ACRIN, ACOSOG, NSABP, and Intergroup trials through the CTSU network. We have enrolled over 5,500 patients onto cooperative group clinical trials over the past forty years and over 600 patients have been enrolled onto therapeutic and non-therapeutic trials since 2007, meeting and exceeding accrual goals in a consistent manner. Our Cancer Center is a unique urban based center of research, patient care and education which is reflected in our recruitment of minorities (24%) and women (52%) onto therapeutic cooperative group trials. All adult cooperative group qualifying Phase II and 1 protocol have been submitted through the CIRB for activation since 2009. Over the years, our faculty members have played an important role in both the administrative and scientific functions of the cooperative groups. Presently, six faculty members hold ten key leadership positions. Since 2007, 25 faculty members have been investigators or co-investigators of 121 cooperative group abstracts or manuscripts, and 18 faculty members have been PI or Co-PIs of 43 cooperative group studies. Since our inception, the cancer programs of WSU/KCI have been organized as multidisciplinary disease programs built on the premise that multidisciplinary clinical research and care provides the best treatment option for patients with cancer Accordingly, the translation of ideas into cooperative group proposals and studies and the incorporation of NCI designated high-priority trials into the WSU/KCI treatment priorities have been easily facilitated. NCI funded trials have the highest priority for activation within our institution. Dr. Lawrence Flaherty, a SWOG member since 1988 and the SWOG U-10 PI since 1996 will serve as the PI of this submission. He was the SWOG Melanoma vice Chair from 1990 until 2011 and has been Chair of the SWOG Data Safety and Monitoring Committee since 2011.
Cancer is the second leading cause of mortality in the United States and disproportionately affects minorities. Clinical research designed and conducted within a consortium of multiple institutions enables faster evaluation of novel therapies, in a variety of malignancies, across different populations nationwide. It also facilitates assessment of scientific correlates that may help assess the effects and individualize cancer therapies.
|Press, Oliver W; Li, Hongli; SchÃ¶der, Heiko et al. (2016) US Intergroup Trial of Response-Adapted Therapy for Stage III to IV Hodgkin Lymphoma Using Early Interim Fluorodeoxyglucose-Positron Emission Tomography Imaging: Southwest Oncology Group S0816. J Clin Oncol 34:2020-7|
|Puvvada, Soham D; Stiff, Patrick J; Leblanc, Michael et al. (2016) Outcomes of MYC-associated lymphomas after R-CHOP with and without consolidative autologous stem cell transplant: subset analysis of randomized trial intergroup SWOG S9704. Br J Haematol 174:686-91|
|Lee, Adam M; Shi, Qian; Alberts, Steven R et al. (2016) Association between DPYD c.1129-5923 C>G/hapB3 and severe toxicity to 5-fluorouracil-based chemotherapy in stage III colon cancer patients: NCCTG N0147 (Alliance). Pharmacogenet Genomics 26:133-7|
|DeBoer, Rebecca; Koval, Gregory; Mulkey, Flora et al. (2016) Clinical impact of ABL1 kinase domain mutations and IKZF1 deletion in adults under age 60 with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL): molecular analysis of CALGB (Alliance) 10001 and 9665. Leuk Lymphoma 57:2298-306|
|Divi, Vasu; Harris, Jonathan; Harari, Paul M et al. (2016) Establishing quality indicators for neck dissection: Correlating the number of lymph nodes with oncologic outcomes (NRG Oncology RTOG 9501 and RTOG 0234). Cancer :|
|Katz, Matthew H G; Shi, Qian; Ahmad, Syed A et al. (2016) Preoperative Modified FOLFIRINOX Treatment Followed by Capecitabine-Based Chemoradiation for Borderline Resectable Pancreatic Cancer: Alliance for Clinical Trials in Oncology Trial A021101. JAMA Surg 151:e161137|
|Nahleh, Z A; Barlow, W E; Hayes, D F et al. (2016) SWOG S0800 (NCI CDR0000636131): addition of bevacizumab to neoadjuvant nab-paclitaxel with dose-dense doxorubicin and cyclophosphamide improves pathologic complete response (pCR) rates in inflammatory or locally advanced breast cancer. Breast Cancer Res Treat 158:485-95|
|Moots, Paul L; O'Neill, Anne; Londer, Harold et al. (2016) Preradiation Chemotherapy for Adult High-risk Medulloblastoma: A Trial of the ECOG-ACRIN Cancer Research Group (E4397). Am J Clin Oncol :|
|Stephens, Deborah M; Li, Hongli; LeBlanc, Michael L et al. (2016) Continued Risk of Relapse Independent of Treatment Modality in Limited-Stage Diffuse Large B-Cell Lymphoma: Final and Long-Term Analysis of Southwest Oncology Group Study S8736. J Clin Oncol 34:2997-3004|
|Buckner, Jan C; Shaw, Edward G; Pugh, Stephanie L et al. (2016) Radiation plus Procarbazine, CCNU, and Vincristine in Low-Grade Glioma. N Engl J Med 374:1344-55|
Showing the most recent 10 out of 35 publications